Updated: Apr 12, 2019
UPDATED - 4/12/19
$GH is SETTING UP & BUILDING CAUSE = EFFECT, en route to retest & very likely take out the $100 century marker.
Given the aggressive volume accumulation on the upswing relative to the muted pullback volume + that GH has cultivated higher lows after a bullish-crossover occurring on both the MACD & Stochastics momentum oscillators, we see far more upside risk than downside risk in this name. Add on the fundamental tailwind of their liquid biopsy test for lung cancer patients to be included in healthcare coverage plans and you have a stock that's a very attractive acquisition target. Who remembers $KITE Pharma when we purchased it around the $70 & $80 area...buying pressure continued as it got well above $120/share...4 months later it was acquired by Gilead & the stock shot up to it's true share price value around $180/share. This stock is very likely being accumulated due to the similar parlay. Acquisition target aside, GH is now primed for significant revenue growth nonetheless.
BotTrigger Trade Alerts (2) : $GH Guardant Health bought the common stock here @ $72.54 for a 5% allocation size AND we're also buying the July 19, 2019 $80 / $100 vertical call-spread here @ $4.75 for a separate 3% allocation size. The call-spread has a maximum value of $20 which is a 320% gain opportunity so long as share price reaches @ $100 or greater than upon expiration. Please note the Breakeven & Max Loss levels that are all illustrated here on this daily chart.
We have a very strong reversal pattern that has been cultivated from this pullback cycle. This was nothing more than a digestion of gains as the stock coils up the energy for the NEXT LEG HIGHER. The technicals here are very strong & being especially complimented by the fundamental news on this stock. BofA issued their 2nd upgrade on this stock just today, and how timely they did so on today's company announcement that Guardant Health's liquid biopsy test will now be covered in health care plans: "Guardant Health's (NASDAQ:GH) liquid biopsy, Guardant360, will be a covered benefit for the members of the health plans associated with eviCore, a technology assessment company....This will increase total lung cancer coverage for Guardant360 to more than 150M Americans, including for all Medicare beneficiaries, members of Cigna, Blue Shield of California, UPMC Health Plan, BCBS FEP (Federal Employees Program), and many others."